TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25089264
Drug: Mebeverine (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine (135 mg, twice daily)
Study: 17467553
Drug: Long-term azithromycin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term azithromycin administration
Study: 10705266
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 500 microg 3 times daily for 2 months
Study: 6476499
Drug: 22% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22% BCAA amino acid solution
Study: 6476499
Drug: 41% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 41% BCAA amino acid solution
Study: 6476499
Drug: Control (41%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (41% BCAA amino acid solution)
Study: 29958022
Drug: Closed loop
Normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed loop insulin delivery during labor and delivery
Study: 29958022
Drug: Closed loop
Normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed loop insulin delivery postpartum
Study: 19592029
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg (group P)
Study: 19592029
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg added to lidocaine (group A)
Study: 19592029
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) solution (group S)
Study: 10532133
Drug: Liquid diet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid diet, sennosides A and B, and a two-liter solution with PEG and electrolytes
Study: 7768070
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (250 ml) before one oral and one intravenous dose of cyclosporine
Study: 7768070
Drug: Intravenous cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclosporine (2.5 mg/kg infused for 3 hours)
Study: 7768070
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine (7.5 mg/kg)
Study: 1691392
Drug: Epinephrine (EPI)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine (EPI) infusion (20 ng kg‐1/min) during placebo
Study: 1691392
Drug: Epinephrine (EPI)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine (EPI) infusion during beta 1‐selective beta‐adrenoceptor blockade with atenolol (50 mg once daily)
Study: 1691392
Drug: Epinephrine (EPI)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine (EPI) infusion during nonselective beta‐blockade with bopindolol (1 mg once daily)
Study: 1691392
Drug: Epinephrine (EPI)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine (EPI) infusion during stress tests
Study: 15795147
Drug: Epinephrine 12.5
Normalized name: Epinephrine 12.5 microgram/mL and lidocaine hydrochloride 20 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 12.5 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Study: 15795147
Drug: Epinephrine 25
Normalized name: EPINEPHRINE 250MCG 300D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 25 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Study: 15795147
Drug: Epinephrine 50
Normalized name: epinephrine 500 MCG per 0.5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 50 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Study: 15795147
Drug: Epinephrine 100
Normalized name: Epinephrine 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 100 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Study: 15795147
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: bupivacaine 2.5 mg and fentanyl 25 microg only
Study: 14576732
Drug: High-dose anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose anthracycline regimens, four cycles given every 15 days as induction lasting for ≤6 months.
Study: 14576732
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy consolidation followed by autologous stem-cell transplantation (23 patients).
Study: 14576732
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy regimens (69 patients).
Study: 10868452
Drug: Caloric liquid
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric liquid bolus (280 kJ) containing paracetamol and 14C-D-xylose administered during late phase II of the intestinal MMC
Study: 10868452
Drug: Caloric liquid
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric liquid bolus (280 kJ) containing paracetamol and 14C-D-xylose administered during phase I of the intestinal MMC
Study: 6657887
Drug: Psychosomatic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosomatic group therapy (including autogenic training and functional relaxation)
Study: 29476687
Drug: Aflibercept on
Normalized name: Aflibercept only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept on a monthly schedule
Study: 29476687
Drug: Bevacizumab on
Normalized name: Bevacizumab only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab on a monthly schedule
Study: 20854235
Drug: Perindopril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril plus indapamide (4 mg-1.25 mg/day)
Study: 18439712
Drug: Apples (0.63
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apples (0.63 kcal/g energy density)
Study: 18439712
Drug: Pears (0.64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pears (0.64 kcal/g energy density)
Study: 18439712
Drug: Oat cookies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat cookies (3.7 kcal/g energy density)
Study: 15621465
Drug: New protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: New protocol (group 2) with oxytetracycline instilled in a fractionated-dose manner following frequent aspirations at 6h intervals
Study: 11739065
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) with sertraline
Study: 11739065
Drug: Sertraline without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline without ERT
Study: 8234999
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg p.o. administered for 60 minutes
Study: 3318609
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin (1 g) 30 minutes before gastrostomy
Study: 3318609
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline as a placebo
Study: 3318609
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin (1 g)
Study: 29231481
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point sticking treatment (adhesive fabric with vaccaria seeds pressed at specific auricular points for 3 to 5 min, administered twice daily for one week)
Study: 21483895
Drug: Three-implant-supported fixed
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-implant-supported fixed dentures (ISFDs)
Study: 21483895
Drug: Two-implant-supported overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant-supported overdentures (IODs)
Study: 10912666
Drug: Interferon plus
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon plus Ursodeoxycholic acid (UDCA) (13‐15 mg/kg/day)
Study: 9454431
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide in crystalline suspension (Volon A 80, 2.0 ml) intrathecally via lumbar puncture on the 5th postoperative day (group A)
Study: 8363378
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin (400 mg every 12 h)
Study: 8363378
Drug: Intravenous ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ofloxacin (400 mg every 12 h, 1-h infusion)
Study: 22159928
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of methylcobalamin (500 mcg, 1 ml solution, three times a week for two weeks)
Study: 17388705
Drug: Olanzapine (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (15-20 mg/day)
Study: 17388705
Drug: Haloperidol (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (15-20 mg/day) with additional blinded benztropine
Study: 2081685
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 or 200 mg once a week for 4 years)
Study: 763217
Drug: Actovegin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (0.5 ml/kg/day for 14 days)
Study: 763217
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution (equivalent amounts)
Study: 26243249
Drug: Etanercept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (10 mg) with bupivacaine (2 mL)
Study: 26243249
Drug: Control (bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (bupivacaine [2 mL])
Study: 22146946
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone and 5 mg tropisetron (group D+T)
Study: 22146946
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone (group D)
Study: 22146946
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tropisetron (group T)
Study: 9834207
Drug: G-CSF treatment
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF treatment (300 microg/m2 intravenously over 1 hour from day 1 of PBSCT)
Study: 1106445
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (500 mg single dose)
Study: 1106445
Drug: Erythromycin stearates
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearates (500 mg single dose)
Study: 1106445
Drug: Erythromycin estolates
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolates (500 mg single dose)
Study: 1106445
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (250 mg every 6 hours for 4 days)
Study: 1106445
Drug: Erythromycin stearates
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearates (250 mg every 6 hours for 4 days)
Study: 12075201
Drug: Biodegradable copolymer
Normalized name: Methacrylic Acid Copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodegradable copolymer screws (poly‐L‐lactic acid 82% and polyglycolic acid 18%)
Study: 8757422
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) at 375 mg and 250 mg b.i.d. for body weight > 60 and < or = 60 kg, respectively
Study: 8757422
Drug: Zidovudine (AZT)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (AZT) maintaining the current dosage
Study: 6884233
Drug: Oral hyposensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hyposensitization (1,750,000 PNU, 3,500,000 NU)
Study: 6884233
Drug: Parenteral hyposensitization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral hyposensitization (1,550 PNU, 3,100 NU)
Study: 25606785
Drug: C1-inhibitor (C1-INH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1-inhibitor (C1-INH, 20 IU/kg/dose)
Study: 25606785
Drug: C1-inhibitor (C1-INH)
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor (C1-INH)
Study: 23744509
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of HAV/MMRV/PCV-7 (Group 1)
Study: 23744509
Drug: Non-concomitant administration
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-concomitant administration of HAV (Group 2)
Study: 15154663
Drug: PS76A2 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS76A2 (10, 30, or 70 ng mistletoe lectin per ml)
Study: 2525460
Drug: Turret nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turret nebulizer with albuterol (250, 250, 500, 1000 micrograms)
Study: 2525460
Drug: Inspiron nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiron nebulizer with albuterol (250, 250, 500, 1000 micrograms)
Study: 25176615
Drug: Entecavir 0.5mg
Normalized name: ENTECAVIR 0.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.5mg daily combined with tenofovir 300 mg
Study: 23350833
Drug: Fesoterodine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine (4 mg, with potential increase to 8 mg at week 4 or 8)
Study: 16753387
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium diet (1,000 mg daily)
Study: 16753387
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium diet (400 mg daily)
Study: 14749743
Drug: Elderberry juice
Normalized name: EUROPEAN ELDERBERRY JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderberry juice (400 mg spray-dried powder containing 10% anthocyanes t.i.d. equivalent to 5 ml elderberry juice for 2 weeks)
Study: 14749743
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of elderberry juice (50 ml) along with a high-fat breakfast
Study: 55029
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose heparin prophylaxis
Study: 55029
Drug: Sodium and
Normalized name: Sodium and/or sodium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium and calcium heparin administered subcutaneously
Study: 26305649
Drug: Long-chain polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain polyunsaturated fatty acids (LCPUFAs) (1 g)
Study: 26305649
Drug: Lutein (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (10 mg)/zeaxanthin (2 mg)
Study: 22054797
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (400-800 mg once daily)
Study: 10997497
Drug: Penciclovir 1%
Normalized name: PENCICLOVIR 1% CREAM.TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penciclovir 1% cream applied 5 times daily for up to 7 days
Study: 10997497
Drug: Acyclovir 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 3% cream
Study: 1484177
Drug: Sertraline (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-200 mg/day for 8 weeks)
Study: 1484177
Drug: Sertraline (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50, 100, or 200 mg/day for 12 weeks)
Study: 6382103
Drug: Doxium (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxium (calcium dobesilate) 1,500 mg daily for 3 months
Study: 31250356
Drug: Broccoli sprout
Normalized name: BROCCOLI SPROUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprout supplementation (15 capsules daily containing 90 mg sulforaphane and 180 mg glucoraphanin)
Study: 27340991
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injections (16 mg/mL)
Study: 25403207
Drug: Extended rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Extended rituximab exposure (375 mg/m²) with 6×R‐CHOP‐14 (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone on a 14-day schedule)
Study: 22522725
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (n = 24)
Study: 19244175
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Selenium and Vitamin E
Study: 15115902
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of bimakalim (0.1, 0.3 or 0.6 mg)
Study: 15115902
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of bimakalim (0.025 or 0.05 mg)
Study: 15115902
Drug: Bimakalim (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimakalim (both high and low doses)
Study: 9853633
Drug: State model
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: State model (consultation about new or changed prescriptions)
Study: 7865090
Drug: 0.3% triclosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% triclosan (topical application)
Study: 2573298
Drug: Procaterol high
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol high dose (0.01 mg/inhalation, two inhalations, three times daily)
Study: 2573298
Drug: Procaterol low
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol low dose (0.01 mg/inhalation, one inhalation, three times daily)
Study: 4605401
Drug: A2/HK/68 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2/HK/68 vaccine
Study: 4605401
Drug: B/Mass/66 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: B/Mass/66 vaccine
Study: 4605401
Drug: Bivalent vaccine
Normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent vaccine (B/Mass/66 and A2/Mtl/68)
Study: 4605401
Drug: Standard aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard aqueous killed bivalent vaccine
Study: 4605401
Drug: Zonally-purified vaccines
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonally-purified vaccines
Study: 31000205
Drug: 2-dimensional treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-dimensional treatment planning
Study: 31000205
Drug: 3-dimensional treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dimensional treatment planning
Study: 26374833
Drug: Ketoacid supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoacid supplementation (12 tablets per day)
Study: 21525519
Drug: Lithium (0.25-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (0.25-0.5 mmol/l), n = 24
Study: 19252768
Drug: Periarterial infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarterial infiltration of 3-5 ml of saline around scalp arteries
Study: 15521369
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of rofecoxib
Study: 1492862
Drug: Dihydroergocristine (DHEC)
Normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine (DHEC) 6 mg once daily
Study: 4023162
Drug: Estrogen-androgen combined
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-androgen combined preparation
Study: 4023162
Drug: Estrogen-alone drug
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-alone drug
Study: 4023162
Drug: Androgen-alone drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-alone drug
Study: 27755279
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) treatment after switch from TAU
Study: 23683464
Drug: Bronchodilator response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bronchodilator response (BDR) test with a cutoff of 12%
Study: 23683464
Drug: Bronchodilator response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bronchodilator response (BDR) test with a cutoff of less than 8%
Study: 20949229
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (BiPAP and standard oxygen therapy)
Study: 6770498
Drug: Antimicrobial prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prophylaxis (oral nonabsorbed antibiotics)
Study: 6770498
Drug: Parenteral administration
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of antibiotics
Study: 30957578
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg
Study: 30957578
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid 250 mg
Study: 30957578
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ALA and mefenamic acid
Study: 29074818
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate 4.8 g daily for 12 weeks
Study: 16498052
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (LF) - 0.5 g fat/kg body weight (BW) per day for 2.5 days